QTc and anti-tuberculosis drugs: A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment

I. Monedero-Recuero, L. Hernando-Marrupe, A. Sánchez-Montalvá, V. Cox, M. Tommasi, J. Furin, C. Y. Chiang, M. Quelapio, K. G. Koura, A. Trébucq, X. Padanilam, G. Dravniece, A. Piubello

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are global concerns, with stagnant treatment success rates of roughly 54% and 30%, respectively. Despite adverse events associated with several DR-TB drugs, newly developed drugs and shorter regimens are bringing hope; recent concern has focused on drugs that prolong the corrected QT interval (QTc). QTc prolongation is a risk factor for torsades de pointe (TdP), a potentially lethal cardiac arrhythmia. While QTc prolongation is used in research as a surrogate marker for drug safety, the correlation between QTc and TdP is not perfect and depends on additional risk factors. The electrocardiogram (ECG) monitoring that has been recommended when new drugs are used has created alarm among clinicians and National Tuberculosis Programmes (NTPs). ECG monitoring is often challenging in high-burden settings where treatment alternatives are limited. According to a review of studies, the prevalence of sudden death directly attributable to TdP by QTc-prolonging DR-TB drugs is likely less than 1%. The risk of death from an ineffective MDR-TB/XDR-TB regimen thus far exceeds the risk of death from arrhythmia. In patients with QTc prolongation who develop cardiac events, other significant risk factors in addition to the drugs themselves are nearly always present. Clinicians and NTPs should be aware of and manage all possible circumstances that may trigger an arrhythmia (hypopotassaemia and human immunodeficiency virus infection are probably the most frequent in DR-TB patients). We present the limited but growing evidence on QTc prolongation and DR-TB management and propose a clinical approach to achieve an optimal balance between access to life-saving drugs and patient safety.

Original languageEnglish
Pages (from-to)1411-1421
Number of pages11
JournalInternational Journal of Tuberculosis and Lung Disease
Volume22
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Tuberculosis
Extensively Drug-Resistant Tuberculosis
Torsades de Pointes
Pharmaceutical Preparations
Cardiac Arrhythmias
Electrocardiography
Virus Diseases
Patient Safety
Sudden Death
Cross-Sectional Studies
Biomarkers
HIV
Safety
Therapeutics
Research

Keywords

  • Bedaquiline
  • Delamanid
  • QT prolongation
  • Short MDR-TB regimen
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Monedero-Recuero, I., Hernando-Marrupe, L., Sánchez-Montalvá, A., Cox, V., Tommasi, M., Furin, J., ... Piubello, A. (2018). QTc and anti-tuberculosis drugs: A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. International Journal of Tuberculosis and Lung Disease, 22(12), 1411-1421. https://doi.org/10.5588/ijtld.18.0423

QTc and anti-tuberculosis drugs : A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. / Monedero-Recuero, I.; Hernando-Marrupe, L.; Sánchez-Montalvá, A.; Cox, V.; Tommasi, M.; Furin, J.; Chiang, C. Y.; Quelapio, M.; Koura, K. G.; Trébucq, A.; Padanilam, X.; Dravniece, G.; Piubello, A.

In: International Journal of Tuberculosis and Lung Disease, Vol. 22, No. 12, 01.12.2018, p. 1411-1421.

Research output: Contribution to journalReview article

Monedero-Recuero, I, Hernando-Marrupe, L, Sánchez-Montalvá, A, Cox, V, Tommasi, M, Furin, J, Chiang, CY, Quelapio, M, Koura, KG, Trébucq, A, Padanilam, X, Dravniece, G & Piubello, A 2018, 'QTc and anti-tuberculosis drugs: A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment', International Journal of Tuberculosis and Lung Disease, vol. 22, no. 12, pp. 1411-1421. https://doi.org/10.5588/ijtld.18.0423
Monedero-Recuero, I. ; Hernando-Marrupe, L. ; Sánchez-Montalvá, A. ; Cox, V. ; Tommasi, M. ; Furin, J. ; Chiang, C. Y. ; Quelapio, M. ; Koura, K. G. ; Trébucq, A. ; Padanilam, X. ; Dravniece, G. ; Piubello, A. / QTc and anti-tuberculosis drugs : A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. In: International Journal of Tuberculosis and Lung Disease. 2018 ; Vol. 22, No. 12. pp. 1411-1421.
@article{ab792859c0134fdca81146a440b450bc,
title = "QTc and anti-tuberculosis drugs: A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment",
abstract = "Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are global concerns, with stagnant treatment success rates of roughly 54{\%} and 30{\%}, respectively. Despite adverse events associated with several DR-TB drugs, newly developed drugs and shorter regimens are bringing hope; recent concern has focused on drugs that prolong the corrected QT interval (QTc). QTc prolongation is a risk factor for torsades de pointe (TdP), a potentially lethal cardiac arrhythmia. While QTc prolongation is used in research as a surrogate marker for drug safety, the correlation between QTc and TdP is not perfect and depends on additional risk factors. The electrocardiogram (ECG) monitoring that has been recommended when new drugs are used has created alarm among clinicians and National Tuberculosis Programmes (NTPs). ECG monitoring is often challenging in high-burden settings where treatment alternatives are limited. According to a review of studies, the prevalence of sudden death directly attributable to TdP by QTc-prolonging DR-TB drugs is likely less than 1{\%}. The risk of death from an ineffective MDR-TB/XDR-TB regimen thus far exceeds the risk of death from arrhythmia. In patients with QTc prolongation who develop cardiac events, other significant risk factors in addition to the drugs themselves are nearly always present. Clinicians and NTPs should be aware of and manage all possible circumstances that may trigger an arrhythmia (hypopotassaemia and human immunodeficiency virus infection are probably the most frequent in DR-TB patients). We present the limited but growing evidence on QTc prolongation and DR-TB management and propose a clinical approach to achieve an optimal balance between access to life-saving drugs and patient safety.",
keywords = "Bedaquiline, Delamanid, QT prolongation, Short MDR-TB regimen, Tuberculosis",
author = "I. Monedero-Recuero and L. Hernando-Marrupe and A. S{\'a}nchez-Montalv{\'a} and V. Cox and M. Tommasi and J. Furin and Chiang, {C. Y.} and M. Quelapio and Koura, {K. G.} and A. Tr{\'e}bucq and X. Padanilam and G. Dravniece and A. Piubello",
year = "2018",
month = "12",
day = "1",
doi = "10.5588/ijtld.18.0423",
language = "English",
volume = "22",
pages = "1411--1421",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "12",

}

TY - JOUR

T1 - QTc and anti-tuberculosis drugs

T2 - A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment

AU - Monedero-Recuero, I.

AU - Hernando-Marrupe, L.

AU - Sánchez-Montalvá, A.

AU - Cox, V.

AU - Tommasi, M.

AU - Furin, J.

AU - Chiang, C. Y.

AU - Quelapio, M.

AU - Koura, K. G.

AU - Trébucq, A.

AU - Padanilam, X.

AU - Dravniece, G.

AU - Piubello, A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are global concerns, with stagnant treatment success rates of roughly 54% and 30%, respectively. Despite adverse events associated with several DR-TB drugs, newly developed drugs and shorter regimens are bringing hope; recent concern has focused on drugs that prolong the corrected QT interval (QTc). QTc prolongation is a risk factor for torsades de pointe (TdP), a potentially lethal cardiac arrhythmia. While QTc prolongation is used in research as a surrogate marker for drug safety, the correlation between QTc and TdP is not perfect and depends on additional risk factors. The electrocardiogram (ECG) monitoring that has been recommended when new drugs are used has created alarm among clinicians and National Tuberculosis Programmes (NTPs). ECG monitoring is often challenging in high-burden settings where treatment alternatives are limited. According to a review of studies, the prevalence of sudden death directly attributable to TdP by QTc-prolonging DR-TB drugs is likely less than 1%. The risk of death from an ineffective MDR-TB/XDR-TB regimen thus far exceeds the risk of death from arrhythmia. In patients with QTc prolongation who develop cardiac events, other significant risk factors in addition to the drugs themselves are nearly always present. Clinicians and NTPs should be aware of and manage all possible circumstances that may trigger an arrhythmia (hypopotassaemia and human immunodeficiency virus infection are probably the most frequent in DR-TB patients). We present the limited but growing evidence on QTc prolongation and DR-TB management and propose a clinical approach to achieve an optimal balance between access to life-saving drugs and patient safety.

AB - Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are global concerns, with stagnant treatment success rates of roughly 54% and 30%, respectively. Despite adverse events associated with several DR-TB drugs, newly developed drugs and shorter regimens are bringing hope; recent concern has focused on drugs that prolong the corrected QT interval (QTc). QTc prolongation is a risk factor for torsades de pointe (TdP), a potentially lethal cardiac arrhythmia. While QTc prolongation is used in research as a surrogate marker for drug safety, the correlation between QTc and TdP is not perfect and depends on additional risk factors. The electrocardiogram (ECG) monitoring that has been recommended when new drugs are used has created alarm among clinicians and National Tuberculosis Programmes (NTPs). ECG monitoring is often challenging in high-burden settings where treatment alternatives are limited. According to a review of studies, the prevalence of sudden death directly attributable to TdP by QTc-prolonging DR-TB drugs is likely less than 1%. The risk of death from an ineffective MDR-TB/XDR-TB regimen thus far exceeds the risk of death from arrhythmia. In patients with QTc prolongation who develop cardiac events, other significant risk factors in addition to the drugs themselves are nearly always present. Clinicians and NTPs should be aware of and manage all possible circumstances that may trigger an arrhythmia (hypopotassaemia and human immunodeficiency virus infection are probably the most frequent in DR-TB patients). We present the limited but growing evidence on QTc prolongation and DR-TB management and propose a clinical approach to achieve an optimal balance between access to life-saving drugs and patient safety.

KW - Bedaquiline

KW - Delamanid

KW - QT prolongation

KW - Short MDR-TB regimen

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85060042358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060042358&partnerID=8YFLogxK

U2 - 10.5588/ijtld.18.0423

DO - 10.5588/ijtld.18.0423

M3 - Review article

AN - SCOPUS:85060042358

VL - 22

SP - 1411

EP - 1421

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 12

ER -